Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison
For patients with triple-class exposed RRMM treated with 2-4 prior lines of treatment, cilta-cel was found to provide superior clinical benefit over ide-cel in terms of response and progression-free survival.
Authors
- Nitin Patel (ORCID: https://orcid.org/0009-0003-5084-5220)
- Patricia Cost
- Joris Diels (ORCID: https://orcid.org/0000-0002-9456-9120)
- Nikoletta K. Lendvai (ORCID: https://orcid.org/0000-0002-9849-4795)
- Suzy Van Sanden
- Heather Burnett (ORCID: https://orcid.org/0000-0003-1269-4276)
- Nieves López‐Muñoz (ORCID: https://orcid.org/0000-0003-0090-6673)
- Jeremy Er
- Tadao Ishida (ORCID: https://orcid.org/0000-0003-3219-3292)
- Jordan Mark Schecter (ORCID: https://orcid.org/0000-0001-5849-0987)
- Simon James Harrison (ORCID: https://orcid.org/0000-0003-4555-6582)
- Teresa Hernando
- Noffar Bar
- João Mendes
Institutions
- The Royal Melbourne Hospital (AU)
- Janssen (Belgium) (BE)
- The University of Melbourne (AU)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Peter MacCallum Cancer Centre (AU)
- Yale University (US)
- Thermo Fisher Scientific (Canada) (CA)
- Hospital Universitario 12 De Octubre (ES)
- Japanese Red Cross Medical Center (JP)
- Janssen (United States) (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2024-08-12
- DOI
- https://doi.org/10.1080/03007995.2024.2391112
- Citations
- 10
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.54